With 1.66 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.45 million shares. During the session, the Healthcare Plans company that operates in wider Healthcare sector, reached to the highest price of $340.7 whereas the lowest price it dropped to was $331.06. The 52-week range on CI shows that it touched its highest point at $370.83 and its lowest point at $253.95 during that stretch. It currently has a 1-year price target of $397.86. With its current market cap of 92.36 billion, CI has annualized dividend of $5.43 while the current yield stands at 1.64%. Beta for the stock currently stands at 0.51.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CI was up-trending over the past week, with a rise of 5.34%, but this was down by -4.82% over a month. Three-month performance dropped to -1.38% while six-month performance fell -3.27%. The stock gained 12.89% in the past year, while it has gained 10.88% so far this year. A look at the trailing 12-month EPS for CI yields 10.60 with Next year EPS estimates of 31.56. For the next quarter, that number is 7.85. This implies an EPS growth rate of 13.60% for this year and 10.74% for next year. EPS is expected to grow by 11.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 10.54%.
Float and Shares Shorts:
At present, 292.50 million CI shares are outstanding with a float of 272.90 million shares on hand for trading. On 2024-10-31, short shares totaled 3.45 million, which was 124.0 higher than short shares on 1727654400. In addition to Mr. David Michael Cordani as the firm’s President, CEO & Chair of the Board, Ms. Noelle K. Eder serves as its Executive VP & Global Chief Information Officer.
Institutional Ownership:
Through their ownership of 0.89606005 of CI’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CI since 26 analysts follow the stock currently. There are 21 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CI analysts setting a high price target of 438.0 and a low target of 355.0, the average target price over the next 12 months is 398.37793. Based on these targets, CI could surge 31.91% to reach the target high and rise by 6.91% to reach the target low. Reaching the average price target will result in a growth of 19.98% from current levels.
Analysts have provided yearly estimates in a range of $28.80206 being high and $28.40203 being low. For CI, this leads to a yearly average estimate of $28.50204.
